<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03831152</url>
  </required_header>
  <id_info>
    <org_study_id>B24CS</org_study_id>
    <nct_id>NCT03831152</nct_id>
  </id_info>
  <brief_title>Extension Study in Primary Distal Renal Tubular Acidosis</brief_title>
  <official_title>A Phase 3B Open-Label Extension Of Study B23CS (ARENA 2) Evaluating The Continued Safety And Efficacy Of ADV7103 In Subjects With Primary Distal Renal Tubular Acidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advicenne Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advicenne Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label study involving longitudinal assessment of the continued safety, tolerability, and&#xD;
      efficacy of ADV7103 in maintaining targeted serum bicarbonate levels, preventing metabolic&#xD;
      acidosis, and preventing hypokalemia in the following groups of subjects with primary dRTA:&#xD;
&#xD;
        1. subjects who participated in Study B23CS and were adherent to the protocol;&#xD;
&#xD;
        2. subjects ≥ 6 months of age who are living in Europe and did not participate in Study&#xD;
           B23CS; and&#xD;
&#xD;
        3. infants younger than 6 months of age&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 21, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Safety of ADV7103 will be assessed by evaluating the frequency of Treatment-Emergent Adverse events as compared to placebo</measure>
    <time_frame>To 30 months</time_frame>
    <description>Number/proportion of subjects presenting with ADV7103 treatment-related adverse events (AEs) during the study, by severity grade.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acidosis, Renal Tubular</condition>
  <arm_group>
    <arm_group_label>Experimental ADV7103</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients receive ADV7103 at their individualized dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADV7103</intervention_name>
    <description>Single group assignment</description>
    <arm_group_label>Experimental ADV7103</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects who participated in Study B23CS must meet all of the following criteria to be&#xD;
        registered into this study:&#xD;
&#xD;
        1. Female or male subjects who participated in Study B23CS and were adherent to the&#xD;
        protocol;&#xD;
&#xD;
        Subjects who did not participate in Study B23CS must meet all of the following criteria to&#xD;
        be registered into this study:&#xD;
&#xD;
          1. Female or male subjects ≤ 65 years of age at time of consent with the following&#xD;
             stipulations:&#xD;
&#xD;
               1. Subjects ≥ 6 months of age must reside in Europe&#xD;
&#xD;
               2. Subjects &lt; 6 months of age must reside in the United States, Canada, or Europe;&#xD;
&#xD;
          2. Subjects &lt; 6 months of age must be able to swallow (not suck) solid food without&#xD;
             difficulty;&#xD;
&#xD;
          3. Subject presents with a previous diagnosis of primary dRTA;&#xD;
&#xD;
          4. Subject ≥ 6 months of age requires ≥ 0.9 mEq/kg/day of alkali therapy to maintain&#xD;
             serum bicarbonate levels above the LLN;&#xD;
&#xD;
          5. Urine pH &gt; 5.5 and serum bicarbonate &gt; 18 mEq/L for subjects ≥ 4 years old or &gt; 17&#xD;
             mEq/L for subjects &lt; 4 years old on alkali therapy and potassium supplementation (if&#xD;
             indicated) on at least one occasion for each within 6 months;&#xD;
&#xD;
          6. European subjects must be included in a social health insurance system and/or in&#xD;
             compliance with the recommendations of the national law in force relating to&#xD;
             biomedical research;&#xD;
&#xD;
          7. Subject or parent/guardian is willing and able to understand and sign informed consent&#xD;
             and willing to comply with protocol instructions; child assent when appropriate; and&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who participated in Study B23CS and meet any of the following criteria will be&#xD;
        considered ineligible for registration into this study:&#xD;
&#xD;
          1. Female subject who is pregnant or lactating or has plans for pregnancy during the&#xD;
             study; or&#xD;
&#xD;
          2. Subject requires therapy with potassium sparing diuretics, angiotensin converting&#xD;
             enzyme inhibitors, angiotensin II receptor blockers, trimethoprim, drospirenone and&#xD;
             other progestins, nephrotoxic antibiotics, penicillins, tacrolimus, or medications&#xD;
             known to delay gastric emptying or otherwise interfere with absorption of study&#xD;
             product.&#xD;
&#xD;
        Subjects who did not participate in Study B23CS and meet any of the following criteria will&#xD;
        be considered ineligible for registration into this study:&#xD;
&#xD;
          1. Female subject who is pregnant or lactating or has plans for pregnancy during the&#xD;
             study;&#xD;
&#xD;
          2. Subject has evidence of proximal tubule dysfunction unless the subject is &lt; 6 months&#xD;
             of age;&#xD;
&#xD;
          3. Subject presents with another diagnosed condition as a potential etiology for her/his&#xD;
             dRTA ;&#xD;
&#xD;
          4. Subject requires therapy with potassium sparing diuretics, angiotensin converting&#xD;
             enzyme inhibitors, angiotensin II receptor blockers, trimethoprim, drospirenone and&#xD;
             other progestins, nephrotoxic antibiotics, penicillins, tacrolimus, or medications&#xD;
             known to delay gastric emptying or otherwise interfere with absorption of study&#xD;
             product;&#xD;
&#xD;
          5. Subject has evidence of obstructive uropathy or other findings on renal ultrasound&#xD;
             expected to require intervention during the course of the study;&#xD;
&#xD;
          6. Subject has any of the following laboratory abnormalities:&#xD;
&#xD;
               1. AST and/or ALT &gt; 1.5x upper limit of normal (ULN)&#xD;
&#xD;
               2. Serum potassium &gt; 5.0 mEq/L or hypokalemia accompanied by clinical symptoms (eg,&#xD;
                  muscle cramps) or significant ECG changes (eg, T wave depression, U wave&#xD;
                  elevation)&#xD;
&#xD;
               3. Estimated glomerular filtration rate (eGFR) &lt; 60 mL/min/1.73 m2 (according to the&#xD;
                  updated Schwartz formula for children and Chronic Kidney Disease - Epidemiology&#xD;
                  Collaboration [CKD-EPI] formula for adults)&#xD;
&#xD;
               4. Total bilirubin &gt; ULN, except with known Gilbert's disease.&#xD;
&#xD;
          7. Subject has been hospitalized or had outpatient surgery (other than minor skin and&#xD;
             dRTA disease-related procedures or ear tube placement) in the past 6 months or is&#xD;
             planning surgery in the next 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Months</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre Ulmann, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Advicenne Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Florida Pediatric Infectious Diseases</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 23, 2019</study_first_submitted>
  <study_first_submitted_qc>February 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2019</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acidosis, Renal Tubular</mesh_term>
    <mesh_term>Acidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

